Skip to main content

NewcelX Ltd.

corporate_fare Company Profile

NewcelX Ltd.

NCEL·NASDAQ·Life Sciences·CIK 0001783036

NewcelX is a clinical-stage pharmaceutical company that develops and manufactures "off-the-shelf," allogeneic, proprietary cell products. These products are based on its technology platform for expanding and differentiating human embryonic stem cells (hESCs) into functional cells. The company's primary focus is on developing and commercializing stem cell-based therapies to cure Type 1 Diabetes (T1D) using stem cell-derived islets. It also aims to replace, restore, and repair diseased and malfunctioning cells in various degenerative diseases through transplantation of healthy, functional cells. NewcelX commercializes proprietary cell lines optimized for treating ALS and other neurodegenerative diseases. Additionally, it utilizes the DOXA small molecules platform for clinical development of drug candidates, primarily for narcolepsy, neuroinflammation, and Diabetes-Associated Neurological Disorders (DANS). NewcelX is primarily developing two cell therapy products. NCEL-101 is the company's lead program for diabetes treatment, consisting of enriched pancreatic islet cells, mainly functional, insulin and glucagon producing and releasing cells. It is intended to treat and potentially cure patients with Type 1 diabetes and possibly Type 2 insulin-dependent diabetes. Other diabetes development programs are in the pipeline, including co-development with academic or commercial entities. AstroRx is NewcelX's platform validation product, an off-the-shelf cryopreserved cell therapy product in clinical development for ALS treatment and in pre-clinical studies for other neurodegenerative indications. AstroRx is comprised of fully differentiated astrocytes, which are the main cells that support the Central Nervous System (CNS). NewcelX is also developing the DOXA (Dual Orexin-Receptor Agonist) small molecules platform for several target indications, including sleep disorders (narcolepsy, idiopathic insomnia), neurodegenerative/neuroinflammation diseases (such as -synucleinopathies), and DANS.

NewcelX Ltd. (NASDAQ:NCEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for NCEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for NCEL spans 6-K, F-3/A, F-3, SCHEDULE 13D.

Recent high-impact activity:

  • NewcelX Raises $1.55M at 20% Premium to Market, Led by Healthcare Investors
  • NewcelX Offloads Mazindol Portfolio for $500K Upfront, Up to $55M in Milestones
  • NewcelX Flags Substantial Doubt About Going Concern as Cash Drops to $710K
  • NewcelX Locks In $1.4M Private Placement at $4.033/Share, a 24% Premium to Market
  • NewcelX Prices $1.4M Private Placement at 20% Premium, Bolstering Diabetes Program

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$8.3M
Diluted EPS
$2.16
Op. Cash Flow
-$2.77M
Free Cash Flow
-$2.77M
Operating Income
-$2.56M
Cash & Equivalents
$2.2M
Total Debt
$355K
Debt / Equity
0.05×
Shares Outstanding
4.8M sh
Source: 20-F · filed 2026-04-29 · accession 0001213900-26-049307

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 10,468 shares in NCEL as of the October 30, 2026 settlement, a 6.9% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 53.7% of NCEL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,468 shares as of October 30, 2026
Change vs prior period▲ 6.9%
Days to cover1.00 at avg daily volume of 10,517
Daily short volume (FINRA facilities)53.7% of 3,858 shares on November 20, 2026
5-day average short volume41.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for NCEL, detected from its recent SEC filings · based on capital-structure filings through 2026-06-30.

1 shelf registration

Shareholder Proposals Approved · Authorization of New Shares

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

NCEL files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$2.48 -2.36% today
52-week range · as of 2026-09-18 $1.83 – $246
Market cap
$13.68M
Volume
5.7K (0.3× avg)
3-mo avg 21.1K
Live data · 2026-11-22 02:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NCEL - Latest Insights

NCEL
Nov 09, 2026, 9:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.34
Real-time Price: $2.48 info
Change: +$0.140 (+6%) info
Market Cap: $13.675M info
NCEL
Nov 04, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.64
Real-time Price: $2.48 info
Change: -$0.160 (-6%) info
Market Cap: $13.675M info
NCEL
Sep 18, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.15
Real-time Price: $2.48 info
Change: -$0.670 (-21%) info
Market Cap: $13.675M info
NCEL
Aug 03, 2026, 4:29 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $2.48 info
Change: -$0.7799 (-24%) info
Market Cap: $13.675M info
NCEL
Jul 31, 2026, 9:11 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $2.48 info
Change: -$1.04 (-30%) info
Market Cap: $13.675M info
NCEL
Jul 08, 2026, 9:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.91
Real-time Price: $2.48 info
Change: -$1.43 (-37%) info
Market Cap: $13.675M info
NCEL
Jul 01, 2026, 9:30 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.94
Real-time Price: $2.48 info
Change: -$1.46 (-37%) info
Market Cap: $13.675M info
NCEL
Jul 01, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.85
Real-time Price: $2.48 info
Change: -$1.37 (-36%) info
Market Cap: $13.675M info
NCEL
Jun 30, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.66
Real-time Price: $2.48 info
Change: -$1.18 (-32%) info
Market Cap: $13.675M info
NCEL
Jun 15, 2026, 8:42 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $2.48 info
Change: -$0.620 (-20%) info
Market Cap: $13.675M info
NCEL
Jun 10, 2026, 4:16 PM EDT
Filing Type: F-3/A
Importance Score:
9
Price at Filing: $3.17
Real-time Price: $2.48 info
Change: -$0.690 (-22%) info
Market Cap: $13.675M info
NCEL
Jun 05, 2026, 4:32 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.85
Real-time Price: $2.48 info
Change: -$0.370 (-13%) info
Market Cap: $13.675M info
NCEL
May 27, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.42
Real-time Price: $2.48 info
Change: -$0.940 (-27%) info
Market Cap: $13.675M info
NCEL
May 11, 2026, 5:06 PM EDT
Filing Type: F-3
Importance Score:
9
Price at Filing: $3.38
Real-time Price: $2.48 info
Change: -$0.900 (-27%) info
Market Cap: $13.675M info
NCEL
May 04, 2026, 4:26 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $3.77
Real-time Price: $2.48 info
Change: -$1.29 (-34%) info
Market Cap: $13.675M info
NCEL
Apr 30, 2026, 8:18 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.69
Real-time Price: $2.48 info
Change: -$1.21 (-33%) info
Market Cap: $13.675M info
NCEL
Apr 30, 2026, 8:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.69
Real-time Price: $2.48 info
Change: -$1.21 (-33%) info
Market Cap: $13.675M info
NCEL
Apr 29, 2026, 4:15 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $3.69
Real-time Price: $2.48 info
Change: -$1.21 (-33%) info
Market Cap: $13.675M info
NCEL
Apr 20, 2026, 7:40 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.63
Real-time Price: $2.48 info
Change: -$0.150 (-6%) info
Market Cap: $13.675M info
NCEL
Apr 01, 2026, 5:03 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.35
Real-time Price: $2.48 info
Change: +$0.130 (+6%) info
Market Cap: $13.675M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets